ArticleClinical and experimental otorhinolaryngology2026
Single-Cell RNA Sequencing Reveals the Heterogeneity and Microenvironment of Temporal Bone Squamous Cell Carcinoma.
Article in Clinical and experimental otorhinolaryngology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesTemporal bone squamous cell carcinoma (TBSCC) is the most common subtype of temporal bone malignancy. However, its low incidence, high misdiagnosis rate, and the difficulty of conducting large-scale studies and clinical trials have limited researchers' understanding of its occurrence and progression, and diagnostic and therapeutic biomarkers remain lacking. Addressing these gaps requires a clearer understanding of TBSCC tumor heterogeneity and microenvironment. This study aimed to characterize the tumor heterogeneity and microenvironment of TBSCC.
methodsSingle-cell RNA sequencing (scRNA-seq) is an effective approach for interrogating tumor heterogeneity. Here, we report scRNA-seq data for TBSCC. We collected and sequenced 113,344 cells from nine samples (five cancer tissues and four histologically verified adjacent normal temporal bone tissues) obtained from six patients with TBSCC.
resultsThe proportion of S-phase cancer cells was higher in samples with tumor invasion, and the pseudotime trajectory of cancer cells closely corresponded with the TBSCC differentiation level. We also detected higher communication intensity between certain immune cell pairs in cancer tissues than in histologically verified adjacent normal temporal bone tissues. In addition, we identified several cancer-related genes as potential diagnostic markers of TBSCC.
conclusionThis study is the first to characterize the complex heterogeneity and tumor microenvironment of TBSCC using scRNA-seq, providing new avenues for diagnosing, classifying, and treating this rare carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.